Pharmacology & Therapeutics, Journal Year: 2024, Volume and Issue: unknown, P. 108774 - 108774
Published: Dec. 1, 2024
Language: Английский
International Journal of Molecular Sciences, Journal Year: 2025, Volume and Issue: 26(4), P. 1778 - 1778
Published: Feb. 19, 2025
In recent years, “metabolic dysfunction-associated steatotic liver disease” (MASLD) has been proposed to better connect disease metabolic dysfunction, which is the most common chronic worldwide. MASLD affects more than 30% of individuals globally, and it diagnosed by combination hepatic steatosis obesity, type 2 diabetes, or two risk factors. begins with buildup extra fat, often greater 5%, within liver, causing hepatocytes become stressed. This can proceed a severe form, steatohepatitis (MASH), in 20–30% people, where inflammation causes tissue fibrosis, limits blood flow over time. As fibrosis worsens, MASH may lead cirrhosis, failure, even cancer. While pathophysiology not fully known, current “multiple-hits” concept proposes that dietary lifestyle factors, genetic epigenetic factors contribute elevated oxidative stress inflammation, fibrosis. review article provides an overview pathogenesis evaluates existing therapies as well pharmacological drugs are currently being studied clinical trials for MASH.
Language: Английский
Citations
1
International Journal of Molecular Sciences, Journal Year: 2024, Volume and Issue: 25(22), P. 12229 - 12229
Published: Nov. 14, 2024
Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as non-alcoholic fatty (NAFLD), is a growing health concern worldwide, affecting more than 1 billion adults. It may progress to metabolic steatohepatitis (MASH), cirrhosis, and ultimately hepatocellular carcinoma (HCC). Emerging evidence has demonstrated the role in this transition of microRNAs (miRNAs), which regulate expression genes associated with lipid metabolism, inflammation, fibrosis, cell proliferation. Specific miRNAs have been identified exacerbate or mitigate fibrotic carcinogenic processes hepatic cells. The modulation these through synthetic mimics inhibitors represents promising therapeutic strategy. Preclinical models that miRNA-based therapies can attenuate reduce inhibit tumorigenesis, thus delaying preventing onset HCC. However, challenges such delivery mechanisms, off-target effects, long-term safety remain be addressed. This review, focusing on recently published preclinical clinical studies, explores pharmacological potential interventions prevent MASLD/MASH progression toward
Language: Английский
Citations
6
Biomolecules, Journal Year: 2025, Volume and Issue: 15(1), P. 121 - 121
Published: Jan. 14, 2025
Chronic hepatobiliary damage progressively leads to fibrosis, which may evolve into cirrhosis and/or hepatocellular carcinoma. The fight against the increasing incidence of liver-related morbidity and mortality is challenged by a lack clinically validated early-stage biomarkers limited availability effective anti-fibrotic therapies. Current research focused on uncovering pathogenetic mechanisms that drive liver fibrosis. Drugs targeting molecular pathways involved in chronic diseases, such as inflammation, hepatic stellate cell activation proliferation, extracellular matrix production, are being developed. Etiology-specific treatments, those for hepatitis B C viruses, already clinical use, efforts develop new, targeted therapies other diseases ongoing. In this review, we highlight major changes occurring patients affected metabolic dysfunction-associated steatotic disease, viral (Delta virus), autoimmune (autoimmune hepatitis, primary biliary cholangitis, sclerosing cholangitis). Further, describe how knowledge linked current well ongoing preclinical novel strategies, including nucleic acid-, mesenchymal stromal/stem cell-, vesicle-based options. Much development obviously still missing, but plethora promising potential treatment strategies holds promise future reversal increase group patients.
Language: Английский
Citations
0
World Journal of Diabetes, Journal Year: 2025, Volume and Issue: 16(4)
Published: Feb. 28, 2025
Diabetes mellitus (DM) is a metabolic disorder characterized by persistent hyperglycemia and other symptoms, which pose significant challenges to individual health, life expectancy, public healthcare systems. The escalating global prevalence of diabetes underscores the need for innovative therapeutic interventions. In this article, we critically comment on study Wang et al, published in World Journal Diabetes, elucidates potential Plantamajoside (PMS) type 2 DM (T2DM) management. authors provide evidence mechanism action PMS T2DM models, demonstrating prevention endoplasmic reticulum stress apoptosis pancreatic β-cells via activation DNAJC1. This manuscript provides brief review pathogenesis T2DM, explores various roles disease therapy addition DNAJC-related apoptotic autophagic functions, evaluates experimental approaches employed recommendations advancing future research.
Language: Английский
Citations
0
Alimentary Pharmacology & Therapeutics, Journal Year: 2025, Volume and Issue: unknown
Published: April 10, 2025
ABSTRACT Background and Aims MicroRNAs (miRNAs) are short non‐coding oligonucleotides involved in the post‐transcriptional regulation of gene expression. We investigated association between miRNome profile circulating extracellular vesicles (EVs) metabolic derangements, hepatic pro‐inflammatory cytokines, liver damage across histological spectrum dysfunction‐associated steatotic disease (MASLD). Methods EV miRNAs expression was determined by NGS (NextSeq550, Illumina Inc) 228 biopsy‐proven MASLD patients. In vivo studies were performed a subgroup 54 patients tracer infusion ([6,6‐ 2 H ]glucose [ 5 ]glycerol) to assess glucose lipid fluxes insulin resistance (IR) adipose tissue. Results Seven (miR‐27b‐3p, miR‐30a‐5p, miR‐122‐5p, miR‐375‐3p, miR‐103a‐3p, let‐7d‐5p, let‐7f‐5p) differentially expressed according diagnosis steatohepatitis presence significant fibrosis ( F ≥ 2), thus marking subjects with ‘at‐risk MASH’. studies, above‐reported had strongest associations metabolism: miR‐122‐5p miR‐375‐3p levels directly correlated free fatty acids (FFAs) tissue (AT)‐IR, while let‐7d‐5p let‐7f‐5p inversely lipolysis, FFAs, progressively decreased AT‐IR severity. addition, which increased increasing degrees AT‐IR. Conclusions Our results suggest an intertwined connection let‐7 family modulating derangements inflammatory pathways MASH’, paving basis for further aiming at investigating their potential therapeutic value.
Language: Английский
Citations
0
JHEP Reports, Journal Year: 2025, Volume and Issue: unknown, P. 101421 - 101421
Published: April 1, 2025
Language: Английский
Citations
0
World Journal of Hepatology, Journal Year: 2024, Volume and Issue: 16(10), P. 1142 - 1150
Published: Oct. 21, 2024
In this editorial, we comment on the article by Mei et al . Nonalcoholic steatohepatitis (NASH) is a severe inflammatory subtype of nonalcoholic fatty liver disease (NAFLD) with pathological features including steatosis, hepatocellular damage, and varying degrees fibrosis. With epidemic metabolic diseases obesity, prevalence NAFLD in China has increased, it now similar to that developed countries; thus, become major chronic China. Human epidemiological data suggest estrogen protective effect NASH premenopausal women sex hormones influence development disease. This review focuses pathogenesis, treatment, relationship between other as well hormone metabolism, aim providing new strategies for treatment NASH.
Language: Английский
Citations
0
World Journal of Hepatology, Journal Year: 2024, Volume and Issue: 16(10), P. 1322 - 1330
Published: Oct. 27, 2024
In this editorial, we comment on the article by Mei et al . Nonalcoholic steatohepatitis (NASH) is a severe inflammatory subtype of nonalcoholic fatty liver disease (NAFLD) with pathological features including steatosis, hepatocellular damage, and varying degrees fibrosis. With epidemic metabolic diseases obesity, prevalence NAFLD in China has increased, it now similar to that developed countries; thus, become major chronic China. Human epidemiological data suggest estrogen protective effect NASH premenopausal women sex hormones influence development disease. This review focuses pathogenesis, treatment, relationship between other as well hormone metabolism, aim providing new strategies for treatment NASH.
Language: Английский
Citations
0
Pharmacology & Therapeutics, Journal Year: 2024, Volume and Issue: unknown, P. 108774 - 108774
Published: Dec. 1, 2024
Language: Английский
Citations
0